VEEVA-SYSTEMS-INC.
Veeva Systems (NYSE: VEEV) today announced that Idorsia Pharmaceuticals Ltd (SIX: IDIA) has selected Veeva Commercial Cloud to enable its digital field force in the U.S., Japan, and countries across Europe. Idorsia is at the forefront of innovative therapies and needed best-in-class cloud technology to drive its global commercial strategy. Veeva Commercial Cloud brings together multichannel engagement, data, content, and analytics to give Idorsia the foundation for digital excellence.
“Veeva is an important partner that has helped us to rapidly scale-up, supporting our growth plans,” said Joseph Bejjani, CIO at Idorsia. “Veeva Commercial Cloud streamlines commercial processes from pre-launch planning to execution and digitally enables our field force to more effectively engage customers.”
Adoption of Veeva Commercial Cloud builds upon Idorsia’s success with Veeva Development Cloud in speeding end-to-end product development. Idorsia is a fast-growing biopharmaceutical company based in Switzerland with a broad portfolio of innovative drugs in its pipeline.
“Idorsia is a visionary company leading the way on digital transformation,” said Peter Gassner, founder and CEO of Veeva. “We’re thrilled to expand our partnership with Idorsia and support their digital strategy as they prepare to bring new medicines to market and help more patients.”
Learn more about Veeva Commercial Cloud at Veeva Commercial & Medical Summit Online, Europe , November 17-18. The event is only open to life sciences industry professionals. Register for the virtual event at veeva.com/Summit .
Additional Information
For more on Veeva Commercial Cloud, visit: veeva.com/eu/CommercialCloud
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Idorsia
Idorsia Ltd is reaching out for more - We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe’s leading biopharmaceutical companies, with a strong scientific core.
Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet – the ideal constellation to bringing R&D efforts to business success.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 800 highly qualified specialists dedicated to realizing our ambitious targets.
About Veeva Systems
Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu .
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005415/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials18.6.2025 06:30:00 CEST | Press release
Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay. This approval comes just two months after gaining NYS approval for our FLT3 ITD MRD Assay. Together these tests represent a critical tool for patients with acute myeloid leukemia (AML), clinicians and pharmaceutical companies. This new approval underscores Invivoscribe’s ongoing commitment to providing the most accurate, standardized measurable residual disease (MRD) testing solutions worldwide. The NPM1 MRD Assay is a pivotal development in the fight against AML, offering an ultra-sensitive DNA sequencing method to accurately measure trace levels of residual leukemia cells in patients with the NPM1 mutation variants. NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases,1 stable over time,2 and, if present in blood at allele
DNP to Take Controlling-Stake in Laxton18.6.2025 03:30:00 CEST | Press release
Maximizing synergies to accelerate the global expansion of biometric info-driven government authentication and security business Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) entered into a share transfer agreement on June 17, 2025 to acquire Cayman Islands-headquartered Rubicon SEZC. Rubicon (a holding company of “Laxton” group) is a global Identity Systems Integrator that provides ID solutions for governments, primarily in developing nations, to register and authenticate personal information. DNP plans to acquire 75% of Rubicon's shares in July and complete the procedures to make the company a Group company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613922077/en/ Products of Laxton DNP will maximize synergies with Laxton in ID cards and card printers. By expanding to government-related business in Africa, Asia, South America, and other regions, we will further grow our authentication and security business, contr
DNP: Operational Launch of 2,500 mm-Width Coating Line to Enhance Production Capacity by 15%18.6.2025 03:20:00 CEST | Press release
- To accommodate large-scale TVs and high-end model demands - Dai Nippon Printing Co., Ltd. (DNP) is pleased to announce the September operational launch of a coating device compatible with 2,500 mm-width high functional optical film at our Mihara Plant in Hiroshima Prefecture. The operational launch of the second wide coating device comes in response to market and consumer needs, and will boost production capacity by more than 15% on an area basis. With the increased capacity, DNP will accommodate the demand for high functional optical film for 65-inch large-screen TVs, with horizontal and vertical dimensions of 1,436.4 mm x 809.0 mm, which are expected to increase at a compound annual growth rate (CAGR) of approximately 6% between 2025 and 20301 on an area basis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613720341/en/ Image of Mihara Plant [Features] Facilitates the efficient manufacture, or imposition, of high fun
Alipay Enables In-Store Payment Functionality in China for AR Glasses in Collaboration with Rokid to Build Immersive Commerce18.6.2025 02:27:00 CEST | Press release
Over 250,000 units of Rokid Glasses have already been ordered, integrated with Alipay’s digital payment technology for AR glasses.The integration of payments into AR glasses supports a future of seamless, intuitive commerce—enabling instant, gesture-based transactions, immersive product discovery, and new ways for businesses to engage customers. Rokid, a pioneer in augmented reality (AR), today launched Rokid Glasses, its latest AR device. In China, the product supports in-store payments facilitated by Alipay’s digital payment technology and multidimensional risk control solution for AR glasses, providing a seamless and secure payment experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617845457/en/ Rokid partners with Alipay to launch China’s first AR glasses with in-store payment capabilities. According to Rokid, the product will begin rolling out to users starting in June 2025, with over 250,000 units already or
SES Successfully Prices €1 Billion Dual-Tranche Bond Offering with Strong 5.5x Oversubscription17.6.2025 22:25:00 CEST | Press release
NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA (THE UNITED STATES), OR TO ANY US PERSON (AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933), OR IN OR INTO ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. SES S.A. today announced the successful launch and pricing of a dual-tranche note offering in which the company has agreed to sell senior unsecured fixed rate notes under its €5,500,000,000 EMTN Programme (the "Notes"). Settlement is expected to take place on 24 June 2025: EUR 500 million of Notes will bear a coupon of 4.125% due in 2030. EUR 500 million of Notes will bear a coupon of 4.875% due in 2033. SES is rated Baa3, negative outlook by Moody’s and BBB, negative outlook by Fitch. SES shall apply the net proceeds of the Notes towards its general corporate purposes, including, without limitation (i) financ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom